Todd Grazia, MD | |
3410 Worth St., Suite 250, Dallas, TX 75246 | |
(214) 820-6856 | |
(214) 820-1474 |
Full Name | Todd Grazia |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 28 Years |
Location | 3410 Worth St., Dallas, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184714768 | NPI | - | NPPES |
40971236 | Medicaid | CO |
Facility Name | Location | Facility Type |
---|---|---|
Baylor University Medical Center | Dallas, TX | Hospital |
Hendrick Medical Center | Abilene, TX | Hospital |
Baylor Scott & White Heart & Vascular Hospital - Dallas | Dallas, TX | Hospital |
Baylor Scott & White All Saints Medical Center Fort Worth | Fort worth, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Healthtexas Provider Network | 1355254210 | 1810 |
News Archive
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups.
A preliminary study adds to evidence that bipolar disorder and epilepsy may be different expressions of common pathways.
› Verified 8 days ago
Entity Name | Healthtexas Provider Network |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1760488936 PECOS PAC ID: 1355254210 Enrollment ID: O20040727001187 |
News Archive
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups.
A preliminary study adds to evidence that bipolar disorder and epilepsy may be different expressions of common pathways.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Todd Grazia, MD 3410 Worth St., Suite 250, Dallas, TX 75246 Ph: (214) 820-6856 | Todd Grazia, MD 3410 Worth St., Suite 250, Dallas, TX 75246 Ph: (214) 820-6856 |
News Archive
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups.
A preliminary study adds to evidence that bipolar disorder and epilepsy may be different expressions of common pathways.
› Verified 8 days ago
Uma B.r.k Pakkivenkata, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |